Biomed. Papers 147(1), 3-10 (2003) | DOI: 10.5507/bp.2003.001

THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. I. PROTEINS OF THE BCL-2 FAMILY AND PROTEIN P53

Jana Knillová, Zdeněk Kolář
Laboratory of Molecular Pathology and Institute of Pathology, Faculty of Medicine, Palacký University, 775 15 Olomouc, Czech Republic

The molecular basis for the transition of carcinoma of the prostate from androgen-dependent to androgen-independent growth is largely unknown. Currently for example, it is not clear whether the androgen-independent phenotype is a result of selection of a subgroup of genetically distinct prostate tumour cells which are already hormone-resistant or a genetic adaptation of prostate tumour cells to the hormone therapy itself. It has also been established that prostate tumour transformation is a result of homeostatic control defects, a line of thinking directed toward elucidating the apoptotic profile of prostate tumour cells that may be important in determining prognosis, response to therapy and illness progression. Main consideration in this part of rewiev is given to the role of Bcl-2 and members of the Bcl-2 family, and tumour suppressor gene p53.

Keywords: Prostate cancer, Apoptosis, Gene expression, Bcl-2 family, p53

Received: April 19, 2003; Published: November 1, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Knillová, J., & Kolář, Z. (2003). THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. I. PROTEINS OF THE BCL-2 FAMILY AND PROTEIN P53. Biomedical papers, 147(1), 3-10. doi: 10.5507/bp.2003.001
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Parkin DM, Pisani P, Ferlay J. (1999) Global cancer statistics. CA Cancer J Clin 49, 33-64. Go to original source... Go to PubMed...
    2. ®aloudík J. (2001) Trendy výskytu zhoubných nádorů v České republice. 118. Internistický den, XVII. Vanýskův den, Brno, p. 8.
    3. Kyprianou N, Isaacs JT. (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122, 552-62. Go to original source... Go to PubMed...
    4. Colombel MR, Buttyan R. (1995) Hormonal control of apoptosis: the rat prostate gland as a model system. Methods Cell Biol 46, 369-85. Go to original source... Go to PubMed...
    5. Bruckheimer EM, Kyprianou N. (2000) Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 301, 153-62. Go to original source... Go to PubMed...
    6. Brinkmann AO. Mechanisms of developing androgen independence in: New perspectives in prostate cancer (Belldegrun A. ed.). Isis Medical Media, Oxford, 1998, p. 77-82.
    7. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H. (1998) Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35, 63-70. Go to original source... Go to PubMed...
    8. Craft N, Sawyers CL. (1999) Mechanistic concepts in androgende- -pendence of prostate cancer. Cancer Metastasis Rev 17, 421-7. Go to original source... Go to PubMed...
    9. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkuma B, Balk SP. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59, 2511-5.
    10. Isaacs JT, Furuya Y, Berges R. (1994) The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5, 391-400.
    11. Coptcoat JJ. The management of advanced prostate cancer. Blackwell Science, Oxford, London, Edinburgh, Cambirdge, Carlton, 1996, p. 8-9.
    12. Bruckheimer EM, Gjertsen, B. T., McDonnell, T. J. (1999) Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 26, 382-98.
    13. Craft N, Shostak Y, Carey M, Sawyers CL. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5. Go to original source... Go to PubMed...
    14. Jenster G. (1999) The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26, 407-21.
    15. Vaarala MH, Porvari K, Kyllonen A, Vihko P. (2000) Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 80, 1259-68. Go to original source... Go to PubMed...
    16. Adams JM, Cory S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-6. Go to original source... Go to PubMed...
    17. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097-9. Go to original source... Go to PubMed...
    18. Chaudhary KS, Abel PD, Lalani EN. (1999) Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 107 Suppl 1, 49-57. Go to original source... Go to PubMed...
    19. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. (1999) Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 457, 217-36. Go to original source... Go to PubMed...
    20. Kelekar A, Thompson CB. (1998) Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 8, 324-30. Go to original source... Go to PubMed...
    21. Adams JM, Cory S. (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26, 61-6. Go to original source... Go to PubMed...
    22. Reed JC. (1997) Double identity for proteins of the Bcl-2 family. Nature 387, 773-6. Go to original source... Go to PubMed...
    23. Knudson CM, Korsmeyer SJ. (1997) Bcl-2 and Bax function independently to regulate cell death. Nat Genet 16, 358-63. Go to original source... Go to PubMed...
    24. Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, Fabbro D, Borner C. (1998) The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 273, 6110-20. Go to original source... Go to PubMed...
    25. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ. (1996) Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148, 1557-65.
    26. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC. (1996) Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone- refractory prostate cancer. Br J Cancer 74, 1258-62. Go to original source... Go to PubMed...
    27. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148, 1567-76.
    28. Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S. (1998) Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 81, 116-21. Go to original source... Go to PubMed...
    29. Hering FL, Lipay MV, Lipay MA, Rodrigues PR, Nesralah LJ, Srougi M. (2001) Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score. Sao Paulo Med J 119, 138-41. Go to original source... Go to PubMed...
    30. Bruckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. (2000) Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 19, 5251-8. Go to original source... Go to PubMed...
    31. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles- -Gerte E, McDonnell T, DAmato R. (2001) Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 93, 208-13. Go to original source... Go to PubMed...
    32. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52, 6940-4. Go to PubMed...
    33. Colombel M, Symmans F, Gil S, OToole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. (1993) Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143, 390-400.
    34. Bai XZ, Masters JR, ODonoghue N, Kirby R, Pan LX, Young M, Stafford M, Parkinson MC (1999) Prognostic markers in clinically localised prostate cancer. Int J Oncol 14, 785-91. Go to original source... Go to PubMed...
    35. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. (1999) Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 161, 1238-43. Go to original source... Go to PubMed...
    36. Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. (2001) Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol 165, 2126-30. Go to original source... Go to PubMed...
    37. Raffo AJ, Kim AL, Fine RL. (1995) Formation of nuclear Bax/ p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 19, 6216-28. Go to original source... Go to PubMed...
    38. Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ. (1998) Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int J Mol Med 1, 953-9. Go to original source... Go to PubMed...
    39. Kyprianou N, King ED, Bradbury D, Rhee JG. (1997) bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70, 341-8. Go to original source... Go to PubMed...
    40. Kajiwara T, Takeuchi T, Ueki T, Moriyama N, Ueki K, Kakizoe T, Kawabe K. (1999) Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol 6, 520-5. Go to original source... Go to PubMed...
    41. Baltaci S, Orhan D, Ozer G, Tolunay O, Gogous O. (2000) Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int 85, 155-9. Go to original source... Go to PubMed...
    42. Diaz JI, Pow-Sang JM, Mora LB, Seigne JD, Cantor AB, Dalton WS. (2000) Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol 5, 149-154. Go to original source... Go to PubMed...
    43. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. (2000) Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 60, 6052-60. Go to PubMed...
    44. Marcelli M, Marani M, Li X, Sturgis L, Haidacher SJ, Trial JA, Mannucci R, Nicoletti I, Denner L. (2000) Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate 42, 260-73. Go to original source... Go to PubMed...
    45. Li B, Dou QP. (2000) Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97, 3850-5. Go to original source... Go to PubMed...
    46. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. (1995) Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55, 735-8. Go to PubMed...
    47. Dorai T, Goluboff ET, Olsson CA, Buttyan R. (1997) Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 17, 3307-12. Go to PubMed...
    48. Dorai T, Perlman H, Walsh K, Shabsigh A, Goluboff ET, Olsson CA, Buttyan R. (1999) A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer 82, 846-52. Go to original source... Go to PubMed...
    49. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57, 229-33.
    50. Haldar S, Basu A, Croce CM. (1998) Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 58, 1609-15.
    51. Basu A, Haldar S. (1998) Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 13, 659-64. Go to original source... Go to PubMed...
    52. Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG. (2001) Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 85, 115-21. Go to original source... Go to PubMed...
    53. Vogelstein B, Kinzler KW. (1992) p53 function and dysfunction. Cell 70, 523-6. Go to original source... Go to PubMed...
    54. Levine AJ. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323-31. Go to original source... Go to PubMed...
    55. Prives C, Hall PA. (1999) The p53 pathway. J Pathol 187, 112-26. Go to original source... Go to PubMed...
    56. Benchimol S. (2001) p53-dependent pathways of apoptosis. Cell Death Differ 8, 1049-51. Go to original source... Go to PubMed...
    57. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-25. Go to original source... Go to PubMed...
    58. Gartel AL, Serfas MS, Tyner AL (1996) p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213, 138-49. Go to original source... Go to PubMed...
    59. Waga S, Li R, Stillman B. (1997) p53-induced p21 controls DNA replication. Leukemia 11 Suppl 3, 321-3.
    60. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, OConnor PM, Fornace AJ, Harris CC. (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96, 3706-11. Go to original source... Go to PubMed...
    61. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. (2000) Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14, 1584-8. Go to original source...
    62. Vogelstein B, Lane D, Levine AJ. (2000) Surfing the p53 network. Nature 408, 307-10. Go to original source... Go to PubMed...
    63. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. (1997) A model for p53-induced apoptosis. Nature 389, 300-5. Go to original source... Go to PubMed...
    64. Johnstone RW, Ruefli AA, Lowe SW. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-64. Go to original source... Go to PubMed...
    65. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87, 8751-5. Go to original source... Go to PubMed...
    66. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85, 1657-69. Go to original source... Go to PubMed...
    67. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. (1997) Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157, 569-74. Go to original source... Go to PubMed...
    68. Ruijter E, Montironi R, van de Kaa C, Schalken J. (2001) Molecular changes associated with prostate cancer development. Anal Quant Cytol Histol 23, 67-88.
    69. Moul JW. (1999) Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 35, 399-407. Go to original source... Go to PubMed...
    70. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. (1995) Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 147, 92-101.
    71. Downing SR, Jackson P, Russell PJ. (2001) Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression, a review of the evidence. Urol Oncol 6, 103-110. Go to original source... Go to PubMed...
    72. Leite KR, Srougi M, Nesralhah LJ, Camara-Lopes LH. (1999) Analysis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma. Braz J Med Biol Res 32, 283-8. Go to original source... Go to PubMed...
    73. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW, Neal DE. (1993) p53 expression and clinical outcome in prostate cancer. Br J Urol 72, 778-81. Go to original source... Go to PubMed...
    74. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB. (1996) An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56, 3814-22.
    75. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. (1996) The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 48, 971-9. Go to original source... Go to PubMed...
    76. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. (1996) Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2, 399-401.
    77. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, Sutherland RL. (2000) Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60, 1585-94.
    78. Leibovich BC, Cheng L, Weaver AL, Myers RP, Bostwick DG. (2000) Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol 163, 1756-60. Go to original source... Go to PubMed...
    79. Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. (1997) The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 79, 190-5. Go to original source... Go to PubMed...
    80. Sasor A, Wagrowska-Danilewicz M, Danilewicz M. (2000) Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Pol J Pathol 51, 31-6.
    81. Cheng L, Leibovich BC, Bergstralh EJ, Scherer BG, Pacelli A, Ramnani DM, Zincke H, Bostwick DG. (1999) p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer 85, 2455-9. Go to original source... Go to PubMed...
    82. Incognito LS, Cazares LH, Schellhammer PF, Kuban DA, Van Dyk EO, Moriarty RP, Wright GL, Somers KD. (2000) Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy. Int J Oncol 17, 761-9. Go to original source... Go to PubMed...
    83. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW. (1999) P53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162, 2040-5. Go to original source... Go to PubMed...
    84. Karaburun Paker S, Kilicarslan B, Cyftcyoglu AM, Oztekin S, Sargin FC, Erdogru T, Baykara M. (2001) Relationship Between Apoptosis Regulator Proteins (bcl-2 and p53) and Gleason Score in Prostate Cancer. Pathol Oncol Res 7, 209-12. Go to original source... Go to PubMed...
    85. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. (1997) Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3, 1389-97.
    86. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ (1999) p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161, 304-8. Go to original source... Go to PubMed...
    87. Lee JM, Bernstein A. (1995) Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14, 149-61. Go to original source... Go to PubMed...
    88. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ (1996) P53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 155, 1685-92. Go to original source... Go to PubMed...
    89. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW. (1998) P53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51, 346-51. Go to original source... Go to PubMed...
    90. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. (1995) Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 55, 3726-31. Go to PubMed...
    91. DiPaola RS, Aisner J. (1999) Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 26, 112-6.
    92. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U. (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80, 546-55. Go to original source... Go to PubMed...
    93. Szende B, Romics I, Torda I, Bely M, Szegedi Z, Lovasz S. (1999) Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. Urol Int 63, 115-9. Go to original source... Go to PubMed...
    94. Cesinaro AM, Migaldi M, Ferrari G, Castagnetti G, Dotti A, De Gaetani C, Ferrari P, Trentini GP. (2000) Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neoadjuvant hormonal therapy. Oncol Res 12, 43-9. Go to original source... Go to PubMed...
    95. Koivisto PA, Rantala I. (1999) Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 187, 237-41. Go to original source... Go to PubMed...
    96. Magi-Galluzzi C, Murphy M, Cangi MG, Loda M. (1998) Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Anal Quant Cytol Histol 20, 343-50.
    97. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. (1995) Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55, 2122-8.
    98. Kyprianou N, Rock S. (1998) Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. Anticancer Res 18, 897-905. Go to PubMed...
    99. Scherr DS, Vaughan ED, Wei J, Chung M, Felsen D, Allbright R, Knudsen BS. (1999) BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162, 12-6; discussion 16-7. Go to original source... Go to PubMed...
    100. Jost CA, Marin MC, Kaelin WG. (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191-4. Go to original source... Go to PubMed...
    101. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W. (1999) Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 39, 94-100. Go to original source... Go to PubMed...
    102. Parsons JK, Gage WR, Nelson WG, De Marzo AM (2001) P63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 58, 619-24. Go to original source... Go to PubMed...
    103. Takahashi H, Fukutome K, Watanabe M, Furusato M, Shiraishi T, Ito H, Suzuki H, Ikawa S, Hano H. (2001) Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. Prostate 47, 85-90. Go to original source... Go to PubMed...

    Return to the content